ANDA 211589, held by Somerset Theraps LLC. Succinylcholine Chloride.
As of Nov 16, 2026, ANDA 211589 (Succinylcholine Chloride), held by Somerset Theraps LLC, was first approved by FDA on Jan 15, 2020, with 2 approved supplements and 0 published complete response letters.
Succinylcholine chloride injection is indicated in adults and pediatric patients: as an adjunct to general anesthesia to facilitate tracheal intubation to provide skeletal muscle relaxation during surgery or mechanical ventilation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 15, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Succinylcholine Chloride20MG/ML · injectable;injection | Succinylcholine Chloride | Rx |
| Oct 2, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 3, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 15, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters